Table 1.
Characteristics of overall population and results of logistic regression analyses comparing participants according to the personal decision to modify DMARD treatment in relation to the context of sanitary crisis.
| Overall participants (n = 252) | Personal decision to reduce or stop DMARD treatment (n = 24) | No personal decision to reduce or stop DMARD treatment (n = 225) | Univariate analysis odds ratios | Multivariate analysis odds ratios | |
|---|---|---|---|---|---|
| General characteristics | |||||
| Age (years) | 61.3 (12.7) | 53.8 (13.3) | 62.2 (12.5) | 0.95 (0.92 to 0.98)*** | |
| Age categories | |||||
| 18 to 44 years | 32 (12.7%) | 6 (25.0%) | 26 (11.6%) | 1 (referent) | 1 (referent) |
| 45 to 64 years | 110 (43.9%) | 15 (62.5%) | 93 (41.5%) | 0.70 (0.25 to 1.98) | 0.77 (0.27 to 2.22) |
| 65 years and older | 109 (43.4%) | 3 (12.5%) | 105 (46.9%) | 0.12 (0.03 to 0.52)*** | 0.15 (0.03 to 0.64)** |
| Female | 191 (75.8%) | 20 (83.3%) | 169 (75.1%) | 1.66 (0.54 to 5.05) | |
| BMI (kg/m2) | 25.3 (5.0) | 25.2 (4.8) | 25.3 (5.1) | 1.00 (0.91 to 1.10) | |
| Urban residency | 80 (32.7%) | 10 (43.5%) | 69 (31.5%) | 1.67 (0.70 to 4.00) | |
| Active smoking | 51 (20.2%) | 4 (16.7%) | 47 (20.9%) | 0.76 (0.25 to 2.32) | |
| Medical history | |||||
| High blood pressure | 69 (27.5%) | 3 (12.5%) | 66 (29.5%) | 0.34 (0.10 to 1.19)* | 0.44 (0.12 to 1.58) |
| Diabetes | 11 (4.4%) | 0 (0.0%) | 11 (4.9%) | Not applicable | |
| MACE | 32 (12.7%) | 2 (8.3%) | 30 (13.3%) | 0.59 (0.13 to 2.64) | |
| Chronic lung disease | 68 (28.1%) | 5 (21.7%) | 63 (29.0%) | 0.68 (0.24 to 1.91) | |
| Severe infection | 47 (18.8%) | 4 (16.7%) | 42 (18.7%) | 0.87 (0.28 to 2.67) | |
| Malignancy | 28 (11.2%) | 1 (4.2%) | 27 (12.1%) | 0.32 (0.04 to 2.44) | |
| RA characteristics | |||||
| Disease duration (years) | 14.9 (10.8) | 13.2 (10.8) | 15.1 (10.8) | 0.98 (0.94 to 1.02) | |
| RF positivity | 194 (79.5%) | 18 (75.0%) | 175 (80.3%) | 0.74 (0.28 to 1.97) | |
| ACPA positivity | 200 (83.0%) | 18 (75.0%) | 181 (84.2%) | 0.56 (0.21 to 1.52) | |
| Erosive disease | 162 (66.4%) | 16 (66.7%) | 145 (65.9%) | 1.38 (0.52 to 3.67) | |
| Past glucocorticoid exposure (≥ 5 mg per day for more than 3 months) | 151 (62.9%) | 14 (58.3%) | 135 (63.1%) | 0.82 (0.35 to 1.93) | |
| RA treatments | |||||
| Methotrexate | 164 (65.6%) | 15 (62.5%) | 149 (66.2%) | 0.85 (0.36 to 2.03) | |
| Hydroxychloroquine | 8 (3.2%) | 1 (4.2%) | 7 (3.1%) | 1.35 (0.16 to 11.4) | |
| Other synthetic DMARD | 23 (9.2%) | 3 (12.5%) | 20 (8.9%) | 1.46 (0.40 to 5.31) | |
| Biological DMARD | 140 (56.0%) | 13 (54.2%) | 126 (56.0%) | 0.93 (0.40 to 2.16) | |
| Targeted synthetic DMARD | 10 (4.0%) | 1 (4.2%) | 9 (4.0%) | 1.04 (0.03 to 8.57) | |
| Glucocorticoids | 62 (24.8%) | 8 (33.3%) | 53 (23.6%) | 1.62 (0.66 to 4.00) | |
| NSAIDs | 45 (18.1%) | 5 (20.8%) | 40 (17.9%) | 1.20 (0.42 to 3.42) |
Reported values are mean (standard deviation) for continuous variables, numbers (percentage) for dichotomous variables. ACPA: anti–citrullinated protein antibody; BMI: body mass index; CI: confidence interval; DMARD: disease modifying anti-rheumatic drug; MACE: major adverse cardiac events; NSAID: non-steroidal anti-inflammatory drug; PGA: patient global assessment; RF: rheumatoid factor. * P-value < 0.20 (P-values < 0.20 in univariate analysis were included in the multivariate model); ** P-value < 0.05; *** P-value < 0.001.